Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaccinex Inc.

0.9800
+0.300044.12%
Volume:159.00
Turnover:145.98
Market Cap:2.62M
PE:-0.11
High:0.9800
Open:0.9800
Low:0.9800
Close:0.6800
Loading ...

Top Midday Decliners

MT Newswires Live
·
18 Dec 2024

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live
·
18 Dec 2024

Crude Oil Down Over 1%; US Industrial Production Declines In November

Benzinga
·
18 Dec 2024

Vaccinex Shares Tumble 63% On Nasdaq Delisting

Dow Jones
·
18 Dec 2024

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

GuruFocus.com
·
18 Dec 2024

Vaccinex Stock to Be Delisted From Nasdaq

MT Newswires Live
·
17 Dec 2024

Vaccinex receives delisting notification from Nasdaq

TIPRANKS
·
17 Dec 2024

Vaccinex Announces Receipt of Delisting Notification From Nasdaq

THOMSON REUTERS
·
17 Dec 2024

BRIEF-Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update

Reuters
·
18 Nov 2024

Vaccinex Q3 EPS $(2.83) vs $(15.25) YoY, Revenue $52K vs $20K YoY; Cash, Cash Equivalents And Marketable Securities As Of Sept. 30 Were $2.9M

Benzinga
·
18 Nov 2024

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
18 Nov 2024

Vaccinex Inc: Qtrly Loss per Share $2.83

THOMSON REUTERS
·
18 Nov 2024

Press Release: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow Jones
·
18 Nov 2024

Vaccinex Provides Update on Activmab® Platform: Multiple Project Deals and Presentation at SITC

THOMSON REUTERS
·
07 Nov 2024

Vaccinex to preset new biomarker data on HNSCC

TIPRANKS
·
05 Nov 2024

Vaccinex Inc - Pepinemab Combination Treatments Show Clinical Benefit in Immunotherapy Resistant Tumors

THOMSON REUTERS
·
05 Nov 2024

Vaccinex Reports Improved Immunity Correlating With Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

THOMSON REUTERS
·
05 Nov 2024

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

TIPRANKS
·
31 Oct 2024

Vaccinex Reports New Findings for Signal-Ad Phase 1B/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (Ctad) Conference in Madrid, Spain

THOMSON REUTERS
·
31 Oct 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

GlobeNewswire
·
31 Oct 2024